
    
      Primary therapy stage:

      Paclitaxel Patients receive six cycles of Paclitaxel (175 mg/mÂ² on days 1 of a 4 week cycle,
      intravenously) plus carboplatin (AUC=5, intravenously on day 1 of a 4 week cycle,
      intravenously) with sequential erlotinib (150 mg/day) on days 8-21 of each cycle.

      Maintenance therapy stage:

      Patients, who complete 6 cycles of therapy without progression or intolerable toxicity,
      receive erlotinib (150 mg/day) as maintenance therapy until progression, intolerable toxicity
      or death.
    
  